27 related news articles for
-
MRFF funding advances Hudson Institute RNA therapies
Hudson Institute of Medical Research has been recognised as a leader in RNA based medicine, with new federal government funding set to accelerate the search for new and better treatments.… Read more
-
Better treatments sooner: Hudson unveils RNAte Platform
Hudson Institute of Medical Research today officially unveiled its world-first RNAte platform that could see vaccines and therapeutic treatments developed faster by being able to rapidly assess their potential inflammation side effects, right here in Victoria.… Read more
-
Controlling inflammation to conquer lung infections
A new treatment that controls the body’s response to influenza virus is shaping as the key to preventing dangerous lung inflammation and damage.… Read more
-
Cancer drug limits COVID inflammation
A cancer drug could play an important role in limiting the damaging effects of lung disease inflammation in COVID-19 patients, thanks to new research at Hudson Institute.… Read more
-
Searching for clues to how RNA triggers the immune system
A young Melbourne scientist will spend the next three years advancing exiting new mRNA research to unlock the secrets to how RNA triggers the immune system to fight infection.… Read more
-
Soy molecule may lead to new anti-inflammatory drug
A naturally occurring molecule found in soy products could hold the clue to a new class of potent anti-inflammatory drugs, targeting diseases ranging from heart conditions to COVID-19.… Read more
-
Victorian government funding boost for new anti-inflammatory treatments
Hudson Institute’s groundbreaking research into new anti-inflammatory treatments has attracted the support of the Victorian government, in recognition of its potential to treat COVID-19 and other infectious diseases.… Read more
-
RNA boost for autoimmune disease
The enormous potential of RNA-based treatments for autoimmune diseases has been recognised by the Victorian government, with a new grant from the mRNA Victoria Research Acceleration Fund.… Read more
-
Making more effective and efficient RNA therapeutics
RNA technology developed by Hudson Institute of Medical Research with the potential to limit inflammatory side-effects of RNA therapeutics such as mRNA vaccines, is the subject of a new licensing deal.… Read more
-
Hudson Institute specialist guiding Victoria’s RNA future
Hudson Institute’s expertise in established and emerging fields of medical research has been recognised, with Research Group Head Dr Minni (Minna-Liisa) Änkö added to mRNA Victoria’s Scientific Advisory Group (SAG).… Read more
-
Lessons from how bats resist COVID could inform new treatments in humans
A paper published in the prestigious journal, Science Immunology, explores the idea that studying bats’ responses to SARS-CoV-2 may provide key insights into how and when to best use existing therapies for COVID-19, and to develop new treatments.… Read more
-
Dr Emily Camm named STEM Ambassador, Science and Technology Australia
Dr Emily Camm named one of 17 STEM Ambassadors by Science and Technology Australia for 2021. … Read more
-
Preparing for the next pandemic
Leading virus scientist, Associate Professor Michelle Tate explains why new treatments are needed alongside vaccines.… Read more
-
US President Donald Trump has COVID-19 and is on a cocktail of experimental drugs. What does this mean for his health?
It is unknown how US President Donald Trump will respond to the experimental immunotherapy given to treat his COVID-19 infection, because the drug has not yet been tested and approved, says Hudson Institute Director and CEO, Professor Elizabeth Hartland.… Read more
-
Key to immune system inflammation discovery
Hudson Institute scientists have discovered the key to how cells turn on inflammation and fight infection, providing the knowledge to potentially reduce or stop destructive inflammation in the future.… Read more
-
Medical research to benefit from Morningside Ventures appointment
Australia’s medical research sector will benefit from the appointment of Hudson Institute inflammation scientist Associate Professor Ashley Mansell to global firm Morningside BioPharma Advisory,… Read more
-
Australia’s largest group of inflammation researchers
Inflammation is at the core of life-threatening severe COVID-19 cases. More than 100 researchers at Hudson Institute investigate… Read more
-
COVID-19 treatment clinical trial underway
The first clinical trial of a potential COVID-19 treatment involving a discovery by Hudson Institute researchers received approval in September.… Read more
-
Kids thank their scientist superheroes amid pandemic
Olive, 11 and her brother Will, 8 wanted to say a big thank you to their scientist heroes for all their hard work to improve people’s lives, including on COVID-19 research.… Read more
-
Sepsis nearly took Dr Michael Gantier’s life. Now he studies it.
My name is Michael Gantier and I am a scientist at Hudson Institute. My lab is working on a potential treatment for life-threatening COVID-19 symptoms, … Read more
-
Cell therapies trial planned for COVID-19
More than 200,000 people have died from COVID-19 since January 2020. While Australia has been relatively spared from the onslaught of infections and deaths, our nation’s scientists need to be part of the global effort to address this pandemic.… Read more
-
Using our immune system to fight COVID-19
There is something unusual about the initial—or innate—immune response to COVID-19 compared to usual influenza patterns. … Read more
-
Inflammation and infectious diseases
Severe COVID-19 infection presents as excessive lung inflammation, involving the build-up of cells and fluid in the lungs. This phenomenon, known as ARDS, restricts breathing and causes damage to the lungs. Severely affected patients will need ventilator assistance in intensive care.… Read more
-
Hyper-acute inflammation in COVID-19
Sepsis is a hyper-acute inflammatory response leading to life-threatening organ dysfunction. Sepsis is usually caused by bacterial infections; however, the COVID-19 pandemic illustrates that hyper-acute inflammation can also be part of viral infections.… Read more
-
US FDA approval sought for clinical trial – potential COVID-19 treatment
Biotech company Noxopharm is seeking approval from the US FDA for a clinical trial in COVID-19 patients of an end-stage prostate cancer drug, following a discovery by Hudson Institute researchers that it could act as an anti-inflammatory.… Read more
-
Our response to COVID-19
Hudson Institute has responded to the coronavirus outbreak (COVID-19) both scientifically and to protect the wellbeing of our staff and community. Our world-leading scientists are applying their expertise in hyper-inflammation, to find ways to reduce the body’s overwhelming inflammatory response and acute respiratory distress that is leading to loss of lives from COVID-19. During this… Read more
-
Cancer drug investigated as anti-inflammatory for lethal conditions including COVID-19
An existing cancer drug could potentially modify a severe hyper-inflammatory ‘storm’ associated with some conditions, which may include the COVID-19 virus, according to Hudson Institute researchers.… Read more